"Immortality protein" fires up the cell's power plants
Protection against the consequences of heart attacks
Altschmied / Haendeler
In the cell nucleus, TERT is a component of the so-called "immortality enzyme" Telomerase, for the discovery of which the Nobel Prize in Physiology or Medicine was awarded in 2009. Meanwhile, it has been shown by the two research groups at HHU, that TERT is also present in mitochondria in the cells of the cardiovascular system. However, until now it has not been possible to clearly distinguish between its functions in these two cell organelles.
For this purpose, Prof. Haendeler and Prof. Altschmied have generated worldwide unique mouse models in which the protein is present in all body cells either exclusively in the nucleus or in the mitochondria. WIth these they were able to demonstrate that mitochondrial, but not nuclear TERT improves mitochondrial function in the heart and reduces the damaged area after a heart attack. This is also reflected in the recovery of cardiac function after infarction. Cardiac muscle cells benefit from the increased mitochondrial function and are protected from cell death. Other cell types also profit from increased mitochondrial function such as fibroblasts, which are essential for stable scarring after an infarction, and endothelial cells, which are needed for vascularization and thus blood supply in the infarct area.
Based on these findings, therapies that increase the amount of TERT in mitochondria appear to be useful in achieving a better healing process after a heart attack. Such an effect occurred in heart tissue of bypass patients after a pressure cuff therapy during which a conventional blood pressure cuff placed on the patient's upper arm is inflated several times in a specific rhythm, which improves mitochondrial functions. First cell culture experiments indicate that an increase in mitochondrial TERT levels can also be achieved by using a plant substance approved as a dietary supplement.
Original publication
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.